Bladder Cancer Monitoring and Detection

Non-muscle invasive bladder cancer (NMIBC) has one of the highest lifetime treatment costs of all cancers.¹ Non-invasive, fast and accurate PCR testing with the GeneXpert® system provides standardised, on-demand and actionable results for the diagnosis of bladder cancer and monitoring of NMIBC patients, enabling improved patient management. That’s the PCRplus advantage.

Challenge

Traditional Methodologies Can Limit Timely & Accurate
Diagnosis and Monitoring of Bladder Cancer

Solution

Fast, Easy-to-Use, Non-invasive, Urine-based PCR Testing in Around 90 Minutes

Learn More

1 Williams S, et al. Estimated costs and long-term outcomes of patients with high-risk non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin in the Veterans Affairs Health System. JAMA Network Open. 2021 Mar 31;4(3):e213800

2 Cussenot O, et al. Assessment of Xpert® Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow up. World Journal of Urology. 2021 March;39(9):3329–3335.

3 Witjes J. Developments in the follow-up of non muscle invasive bladder cancer: what did we learn in the last 24 months: a critical review. Curr Opin Urol. 2020 May;30(3):387-391.

4 Kenrick N, et al. Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era. Nat Rev Urol. 2021 Apr;18(4):185-187.

5 Xpert® Bladder Cancer Detection Package Insert: Insert 301-2414, Rev D.

6 Xpert® Bladder Cancer Monitor Package Insert: 301-5933, Rev D.

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.